Adc Therapeutics Sa · NYSE:ADCT
Adc Therapeutics Sa — Investor Presentation (August 2026)
62 slides from Adc Therapeutics Sa's investor presentation, August 2026
Slide 1: Corporate Presentation
Corporate Presentation AUGUST 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a reco
Slide 3: A Pioneer in ADCs with Significant Growth Opportunity from ZYNLONTA
ADC Therapeutics: A Pioneer in ADCs with Significant Growth Opportunity from ZYNLONTA® Potential to address a multi-billion-dollar US market opportunity across 2L+ DLBCL and 2L+ indolent lymphomas Accelerated approval as a monotherapy in 3L+ DLBCL with steady revenue stream Evaluating ZYNLONTA regul
Slide 4: ZYNLONTA is an Approved, Highly-potent, Single-agent Anti-CD19 ADC in r/r DLBCL
ZYNLONTA is an Approved, Highly-potent, Single-agent Anti-CD19 ADC in r/r DLBCL ZYNLONTA ANTI-CD19 ADC Rapid, deep, durable efficacy Malignant in 3L+ DLBCL B Cell DNA damage induced Accessible across care settings Binding to CD19 apoptosis on cell-surface Binding of cytotoxic Endocytosis of PBD payl
Slide 5: Advancing ZYNLONTA Development into 2L+ B-Cell Lymphomas
Advancing ZYNLONTA Development into 2L+ B-Cell Lymphomas DLBCL Indolent Lymphomas • 2L+ treatment choice is based largely on achieving a rapid • 2L+ treatment choice is driven by tolerability and QoL as well and durable complete response, within the accessible as rate and durability of overall respo
Slide 6: DLBCL
DLBCL
Slide 7: 2L+ DLBCL market projected to be ~$3Bn in U.S. by 2030
2L+ DLBCL market, comprised of two key segments, projected to be ~$3Bn in U.S. by 2030* Current 2L+ DLBCL U.S. Market + Broadly Complex 5% Accessible Therapies 10% Therapies Broadly accessible 20% outpatient therapies 2L 20% which can be ~12k patients 10% Bispecifics administered across CAR-T care s
Slide 8: LOTIS-5: Phase 3 Confirmatory Trial of ZYNLONTA in Combination with Rituximab
LOTIS-5: Phase 3 Confirmatory Trial of ZYNLONTA in Combination with Rituximab in 2L+ DLBCL Key Inclusion Criteria Clinical Trial Design Endpoints Cycles 1- 2 Cycles 3 – (up to) 8 Primary endpoint ZYNLONTA ZYNLONTA PFS by IRC 150 µg/kg 75 µg/kg r/r DLBCL with ≥ 1 + + prior therapy Randomized Rituxima
Slide 9: LOTIS-5: Baseline Patient Characteristics
LOTIS-5: Baseline Patient Characteristics Patient population enrolled generally balanced between arms ZYNLONTA+R R-GemOx ZYNLONTA+R R-GemOx Characteristic n=210 (%) n=210 (%) Characteristic n=210 (%) n=210 (%) Median age yr [range] 73 [34,91] 72 [27,91] DLBCL Subtype ≥75 years 87 (41.4%) 79 (37.6%)
Slide 10: LOTIS-5: Efficacy
LOTIS-5: Efficacy Summary of key results Study met primary PFS endpoint with statistical significance (HR=0.73, two-sided p-value 0.008) Higher CR rate with ZYNONTA + rituximab vs R-GemOx (~40% vs ~27%) Longer duration of CRs with higher proportion maintained at 24-months (~49% vs. ~17%) in ZYNLONTA
Slide 11: LOTIS-5: Progression Free Survival by IRC
LOTIS-5: Progression Free Survival by IRC Met primary endpoint of PFS with statistical significance Median PFS, months (95% CI) Event-free rate (95% CI) Lonca-R, % R-GemOx,% ZYNLONTA+R: 6.14 (4.99, 8.11) 1. R-GemOx: 4.73 (2.83, 5.55) 6M 50.4 (43.0, 57.3) 38.9 (31.4, 46.3) . Hazard Ratio (95% CI): 0.
Slide 12: LOTIS-5: Progression Free Survival by Investigator Assessment
LOTIS-5: Progression Free Survival by Investigator Assessment Difference from IRC assessment reflects lower censoring in investigator reported data Median PFS, months (95% CI) ZYNLONTA+R: 5.49 (4.76, 7.89) 1. R-GemOx: 3.02 (2.63, 4.96) . Hazard Ratio (95% CI): 0.65 (0.51, 0.81) . Nominal p-value: 0.
Slide 13: Time to Treatment Failure
LOTIS-5: Time to Treatment Failure ZYNLONTA + rituximab time to treatment failure (PD, death, NALT or discontinuation) longer than that of R-GemOx uc imi u i al s ima es 1. i um e u ec s a isk Median, months ZYNLONTA+R: 5.19 . R-GemOx: 2.76 Hazard Ratio (95% CI): 0.64 (0.518, 0.786) a ili y Nominal
Slide 14: LOTIS-5: Overall Response Rate by IRC
LOTIS-5: Overall Response Rate by IRC Improvement in ORR and CR demonstrated with ZYNLONTA + rituximab vs R-GemOx ORR: 58% (n=122) ORR: 45% PR: 19% (n=95) (n=39) PR: 19% (n=39) CR: 40% (n=83) CR: 27% (n=56) ZYNLONTA + rituximab R-GemOx (n=210) (n=210) Percentages may not add due to rounding. Median
Slide 15: Duration of Response/Complete Response by IRC
LOTIS-5: Duration of Response/Complete Response by IRC At 24 months, 48.5% of patients achieving CR remained in CR with ZYNLONTA + rituximab vs 16.7% with R-GemOx Duration of Response Duration of Complete Response Median DOR, months (95% CI) Median DoCR, months (95% CI) 1. 1. ZYNLONTA+R: 9.20 (7.23,
Slide 16: LOTIS-5: Overall Survival
LOTIS-5: Overall Survival Key secondary efficacy endpoint of OS showed no detrimental effect Median OS, months (95% CI) # of Event/Censored 1. ZYNLONTA+R: 12.19 (10.18, 15.05) . R-GemOx: 12.16 (9.07, 15.38) Event/Censored ZYNLONTA+R R-GemOx Total . Description n=210 n=210 n=420 Hazard Ratio (95% CI)
Slide 17: LOTIS-5: Safety
LOTIS-5: Safety Summary of key results Overall TEAE rates similar between arms imila a es e all G a e ≥3 A s >5% were observed across both arms • Hematologic TEAEs were higher with R-GemOx • Infection, hepatotoxicity and edema/effusion were higher with ZYNLONTA + rituximab SAEs, TEAEs leading to stu
Slide 18: LOTIS-5: Overall Summary of Treatment Emergent Adverse Events
LOTIS-5: Overall Summary of Treatment Emergent Adverse Events ZYNLONTA+R (n=204) R-GemOx (n=197) n (%) n (%) Patients with any TEAE 201 (98.5%) 192 (97.5%) Patients with any grade 3 or higher TEAE 151 (74.0%) 150 (76.1%) Patients with any TEAE related to any study drug 175 (85.8%) 178 (90.4%) Patien
Slide 19: LOTIS-5: Grade 3 or Higher TEAEs >5%
LOTIS-5: Grade 3 or Higher Treatment Emergent Adverse Events >5% ZYNLONTA+R (n=204) R-GemOx (n=197) Grouped Term / Preferred Term n (%) n (%) Patients with any grade 3 or higher TEAE 151 (74.0%) 150 (76.1%) Blood and lymphatic system disorders (SOC) 83 (40.7%) 117 (59.4%) Neutropenia 52 (25.5%) 67 (
Slide 20: Time from First Dose to Key Safety Events
LOTIS-5: Time from First Dose to Key Safety Events* Rates of TEAEs impacted by longer overall TEAE observation time in ZYNLONTA + rituximab vs R-GemOx uc imi u i al s ima es i um e u ec s a isk 1. Median, months ZYNLONTA+R: 2.10 R-GemOx: 0.92 . Longer time from first dose Hazard Ratio (95% CI): 0.66
Slide 21: LOTIS-5: Cause of Grade 5 Treatment Emergent Adverse Events
LOTIS-5: Cause of Grade 5 Treatment Emergent Adverse Events ZYNLONTA+R R-GemOx ZYNLONTA+R R-GemOx SOC Term / Preferred Term n=27 n=9 n=27 n=9 Infections and Infestations 15 5 % of all treated Pneumonia 9 1 patients ≥75 years 40.2% 36.7% Sepsis 3 4 of age COVID-19 1 0 % of all Grade 5 Other Infection
Slide 22: LOTIS-5: Status and planned next steps
LOTIS-5: Status and planned next steps ▪ Met with U.S. FDA in early August 2026 ▪ Totality of topline data discussed Recent ▪ Final meeting minutes from FDA received milestones ▪ FDA feedback indicated substantial concerns regarding the benefit-risk or verification of clinical benefit observed in th
Slide 23: LOTIS-7: Phase 1b trial of ZYNLONTA plus glofitamab
LOTIS-7: Phase 1b trial of ZYNLONTA plus glofitamab Completed enrollment of ~100 patients at ZYNLONTA 150 µg/kg starting dose Key Inclusion Criteria Clinical Trial Design Endpoints ZYNLONTA Part 1 escalating doses of 90, 120*, or 150* µg/kg IV, Q3W Dose escalation + Primary endpoint r/r DLBCL, FL, M
Slide 24: LOTIS-7: Overall Response Rate
LOTIS-7: Overall Response Rate r/r Large B-Cell Lymphoma Efficacy Evaluable Population+ (N=49) as of data cutoff of Nov 17, 2025 120 µg/kg 150 µg/kg ZYNLONTA starting dose* ZYNLONTA starting dose* Total + glofitamab + glofitamab ORR: 95% (n=20) ORR: 90% ORR: 86% (n=44) PR: 14% (n=24) (n=3) PR: 12% P
Slide 25: LOTIS-7: Overall Response Rate (Primary Refractory & Relapsed)
LOTIS-7: Overall Response Rate (Primary Refractory & Relapsed) r/r Large B-Cell Lymphoma Efficacy Evaluable Population+ (N=49) as of data cutoff of Nov 17, 2025 120 µg/kg 150 µg/kg ZYNLONTA starting dose* ZYNLONTA starting dose* Total + glofitamab + glofitamab ORR: 100% ORR: 100% ORR: 100% (n=14) (n
Slide 26: LOTIS-7: Efficacy Over Time
LOTIS-7: Efficacy Over Time r/r Large B-Cell Lymphoma Efficacy Evaluable Population+ (N=49) as of data cutoff of Nov 17, 2025 ZYNLONTA 120 µg/kg* → → → (120 ug/kg) 184-705* 1 → 335-702 2 → → 164-704 3 → → → 121-706 → 4 177-703a → Most responses 5 → + glofit 121-710 → 6 → 121-709 7 → 107-705 → observ
Slide 27: LOTIS-7: Safety Overview
LOTIS-7: Safety Overview r/r Large B-Cell Lymphoma Efficacy Evaluable Population+ (N=49) as of data cutoff of Nov 17, 2025 ZYNLONTA 120 ZYNLONTA 150 All µg/kg* µg/kg* n=49 n=21 n=28 Combination generally well tolerated Gr 3/4 Adverse Events of Special Interest (≥ 5%)a,b Edema and Effusion 16 (76.2%)
Slide 28: ZYNLONTA + glofitamab has Potential to Disrupt r/r DLBCL Complex Therapy Segment
ZYNLONTA + glofitamab has Potential to Disrupt r/r DLBCL Complex Therapy Segment, Unlocking Significant Growth Opportunity Complex Therapies DLBCL Opportunity • Bispecifics are the fastest growing class in r/r DLBCL and have the potential to be Complete Response Rate (%) the largest among complex th
Slide 29: LOTIS-7: Status and potential next steps
LOTIS-7: Status and potential next steps ▪ Target of ~100 patients completed enrollment at selected 150 µg/kg dose in June 2026 Recent milestones ▪ Full data demonstrating potential best-in-class bispecific combination with a safety profile generally consistent with prior disclosures submitted for p
Slide 30: Indolent Lymphomas
Indolent Lymphomas
Slide 31: ZYNLONTA Potential Role in Treatment of 2L+ MZL
ZYNLONTA has the Potential to Play a Meaningful Role in the Treatment of 2L+ MZL 2L+ MZL treatment landscape ZYNLONTA differentiation based on initial phase 2 IIT data • Indolent disease – tolerability and quality of life as important as efficacy • No standardized treatment • CR rate is a key progno
Slide 32: Phase 2 Open-label IIT of ZYNLONTA in 2L+ MZL
Phase 2 Open-label IIT Evaluating Safety and Efficacy of ZYNLONTA in Patients with 2L+ MZL A multi-institutional study, estimated to enroll 50 patients Key Inclusion Criteria Clinical Trial Design Endpoints Primary endpoint r/r ZL with ≥ 1 prior Cycles 1 - 2 Cycles 3 - 6 CR after 6 cycles therapy (L
Slide 33: ZYNLONTA in 2L+MZL: Phase 2 IIT Efficacy Overview
ZYNLONTA in 2L+MZL: Phase 2 IIT Efficacy Overview After median follow-up of 12.2 months, CR was maintained in 17 out of 18 patients, with longest duration of CR of 27 months Response Rates Progression Free Survival ORR: 85% (n=22) PR: 15% (n=4) 100 75 PFS (%) Events/N Month PFS (95% CI) 50 2/27 12 9
Slide 34: ZYNLONTA in 2L+ MZL: Phase 2 IIT Safety Overview
ZYNLONTA in 2L+ MZL: Phase 2 IIT Safety Overview Initial data suggest manageable safety consistent with known profile of ZYNLONTA Patients (n=27) TEAE, n (%) Any grade Grade 3 Grade 4 Maculopapular rash 16 (59.3) 1 (3.7) 0 Increased AST 16 (59.3) 0 0 Adverse events were most commonly Increased ALT 1
Slide 35: ZYNLONTA + rituximab May Provide Significant Benefit to High-Risk 2L+ FL Patients
ZYNLONTA + rituximab May Provide Significant Benefit to High-Risk 2L+ FL Patients 2L+ FL treatment landscape ZYNLONTA + R differentiation based on initial phase 2 IIT data • Indolent disease – tolerability and quality of life as important as efficacy • No standard treatment for r/r FL • High-risk FL
Slide 36: Phase 2 Open-label IIT of ZYNLONTA + rituximab in 2L+ FL
Phase 2 Open-label IIT Evaluating Safety and Efficacy of ZYNLONTA + rituximab in Patients with 2L+ FL Key Inclusion Criteria Clinical Trial Design* Endpoints Induction phase Maintenance phase† Cycles 1- 2 Cycles 3 – 4 Cycles 5-6 Primary endpoint r/r FL grade 1, 2, or 3A CR at week 12 Q3W Q3W Q8W wit
Slide 37: ZYNLONTA + rituximab in 2L+ FL: Updated Phase 2 IIT Efficacy Overview
ZYNLONTA + rituximab in 2L+ FL: Updated Phase 2 IIT Efficacy Overview After median follow-up of 28 months, median PFS was not reached with an 88% PFS at 24-months Best Overall Response Progression Free Survival of Follow-Up of Evaluable Patients ORR: 98% (n=54) PR: 15% (n=8) 100 11% 75 PFS (%) Event
Slide 38: ZYNLONTA + rituximab in 2L+ FL: Phase 2 IIT Safety Overview
ZYNLONTA + rituximab in 2L+ FL: Phase 2 IIT Safety Overview Initial data (n=39) suggest manageable safety consistent with known profile of ZYNLONTA ≥15% for All Grades in 39 Patients 1 AEs, n (%) Grade 1-2 Grade 3 Grade 4 Most TEAEs were grade 1 or 2; Hematological AEs the most common grade ≥3 T A w
Slide 39: Backup slides
Backup slides
Slide 40: LOTIS-2 Final Analysis: Long-Term Efficacy
LOTIS-2 Final Analysis: Long-Term Efficacy Response Rates All Responders Patients in CR Endpoint (n=70) (n=36) ORR: 48% (n=70)b Median cycles of Lonca (range) 3.0 (1-26) 8.0 (1-26) Median time to response (range) 41 days (35-247) 42 days (36-247) mDOR (95% CI) 13.4 months (6.9-NE) Not reached CR 25%
Slide 41: LOTIS-2 Final Analysis: Safety Profile
LOTIS-2 Final Analysis: Safety Profile All-treated Population (N = 145) All-treated Population (N = 145) All grades, n (%) Grade ≥3, n (%) All grades, n (%) Grade ≥3, n (%) Any TEAE 143 (98.6) 107 (73.8) Increased ALT 22 (15.2) 4 (2.8) Increased GGT 61 (42.1) 25 (17.2) Decreased appetite 22 (15.2) -
Slide 42: LOTIS-5: Drug Exposure
LOTIS-5: Drug Exposure (Safety Population N=401) ZYNLONTA+R R-GemOx Characteristic (N=204) (N=197) Number of Cycles Median 5 5 Range (1,8) (1,8) Duration of Treatment (Days) Median 107 77 Range (7,492) (9,233) Relative Dose Intensity* 96% for ZYNLONTA only 92% for rituximab 89% for gemcitabine 87% f
Slide 43: LOTIS-5: Progression Free Survival
LOTIS-5: Progression Free Survival Breakdown of disease progression, death and censoring rates by IRC and Investigator Assessment PFS events by IRC PFS events by Investigator Assessment # of Event/Censored # of Event/Censored Event/Censored Lonca-R R-GemOx Total Event/Censored Lonca-R R-GemOx Total
Slide 44: LOTIS-5: Forest Plot of Progression Free Survival by IRC
LOTIS-5: Forest Plot of Progression Free Survival by IRC In favor of In favor of ZYNLONTA+R R-GemOx ITT population, N=420; Data cut off: February 16, 2026. Corporate Presentation | 44
Slide 45: LOTIS-5: PFS Analyses Using IPCW Method
LOTIS-5: PFS Analyses Using IPCW Method Median: Median: 5.375.37 vs 3.02 vs 3.02 Months Months HR:HR: 0.670.67 (0.54, (0.54, 0.82) 0.82)
Slide 46: LOTIS-5: Prespecified Analysis: PFS by IRC by Age
LOTIS-5: Prespecified Analysis: Progression Free Survival by IRC by Age < 75 years old ≥ 75 years old Median PFS, months (95% CI) Median PFS, months (95% CI) ZYNLONTA+R: 8.28 (5.13, 10.18) ZYNLONTA+R: 5.22 (3.81, 6.60) 1. R-GemOx: 3.15 (2.53, 5.59) 1. R-GemOx: 5.13 (3.98, 7.85) . Hazard Ratio (95% C
Slide 47: LOTIS-5: OS Analyses Using IPCW Method
LOTIS-5: OS Analyses Using IPCW Method Median: 18.23 vs 14.42 Months HR: 0.82 (0.72, 0.93)
Slide 48: LOTIS-5: Prespecified Analysis: Overall Survival by Age
LOTIS-5: Prespecified Analysis: Overall Survival by Age < 75 years old ≥ 75 years old Median OS, months (95% CI) Median OS, months (95% CI) ZYNLONTA+R: 13.47 (10.78, 23.03) 1. ZYNLONTA+R: : 9.86 (7.16, 12.29) 1. R-GemOx: 10.97 (8.21, 14.26) R-GemOx: 13.90 (8.97, NE) . . . Hazard Ratio (95% CI): 0.72
Slide 49: LOTIS-5: TEAEs Leading to Any Study Drug Withdrawal
LOTIS-5: Treatment Emergent Adverse Events Leading to Any Study Drug Withdrawal >2% in Either Treatment Arm by Group Term or Preferred Term Grouped Term* / Preferred Term ZYNLONTA+R (N=204), n (%) R-GemOx (N=197), n (%) Patients with TEAE leading to any study drug withdrawal 52 (25.5%) 18 (9.1%) Inf
Slide 50: LOTIS-5: Serious Treatment Emergent Adverse Events
LOTIS-5: Serious Treatment Emergent Adverse Events >2% in Either Treatment Arm by Group Term or Preferred Term Group Term* / Preferred Term ZYNLONTA+R (N=204),n (%) R-GemOx (N=197), n (%) Patients with any serious TEAE 100 (49.0%) 68 (34.5%) Infections and infestations (SOC) 48 (23.5%) 29 (14.7%) Pn
Slide 51: LOTIS-7: Phase 1b Trial: Baseline Patient Characteristics
LOTIS-7: Phase 1b Trial: Baseline Patient Characteristics r/r Large B-Cell Lymphoma Efficacy Evaluable Population (N=49) as of data cutoff of Nov 17, 2025 120 µg/kg 150 µg/kg N=49 120 µg/kg 150 µg/kg N=21 N=28 N=49 N=21 N=28 Median age [years (range)] 70 (50-82) 71 (26-85) 70 (26-85) IPI Score Male
Slide 52: LOTIS-7: Phase 1b Trial: Safety Summary
LOTIS-7: Phase 1b Trial: Safety Summary r/r Large B-Cell Lymphoma Efficacy Evaluable Population (N=49) as of data cutoff of Nov 17, 2025 120 µg/kg (n=21) 150 µg/kg (n=28) All (n = 49) Grade 3/4 TEAEs (≥ 5% of patients)a 18 (85.7%) 21 (75.0%) 39 (79.6%) Neutropenia 7 (33.3%) 9 (32.1%) 16 (32.7%) GGT
Slide 53: LOTIS-7: Phase 1b Trial: Safety Summary
LOTIS-7: Phase 1b Trial: Safety Summary r/r Large B-Cell Lymphoma Efficacy Evaluable Population (N=49) as of data cutoff of Nov 17, 2025 120 µg/kg 150 µg/kg All Patients with TEAEs leading to study drug discontinuationa n=21 n=28 n = 49 TEAE leading to ZYNLONTA and glofitamab discontinuation 0 3 (10
Slide 54: LOTIS-7: Phase 1b Trial: CRS/ICANS Profile & Management
LOTIS-7: Phase 1b Trial: CRS/ICANS Profile & Management r/r Large B-Cell Lymphoma Efficacy Evaluable Population (N=49) as of data cutoff of Nov 17, 2025 120 µg/kg 150 µg/kg All n = 21 n = 28 n = 49 Cytokine Release Syndrome a Any grade 11 (52.4%) 7 (25.0%) 18 (36.7%) Grade 1 and 2 CRS cases managed
Slide 55: ZYNLONTA in r/r MZL: Patient Baseline Characteristics
ZYNLONTA in r/r MZL: Patient Baseline Characteristics Baseline characteristics Patients (N=27)a Previous treatments Patients (N=27) Median age (range), years 67 (44-82) Median number of previous line of treatment (range) 2 (1-4) Gender (M:F) 8:19 Relapsed, n (%) 17 (63) Race, n (%) Refractory, n (%)
Slide 56: ZYNLONTA in r/r MZL: Initial Efficacy Results (continued)
ZYNLONTA in r/r MZL: Initial Efficacy Results (continued) (A) PFS, (B) OS, (C) Duration of Response, and (D) Duration of CR A. PFS in 27 patients B. OS in 27 patients 100 100 75 75 PFS (%) OS (%) 50 50 Events/N Month PFS (95% CI) 25 2/27 12 92.9 (59.1-99.0%) 25 0 0 6 12 18 24 30 0 0 6 12 18 24 30 Mo
Slide 57: ZYNLONTA + rituximab in r/r FL: Baseline Characteristics
ZYNLONTA + rituximab in r/r FL: Baseline Characteristics Patient demographics (N = 39) Prior treatment characteristics (N = 39) Age, median (IQR), years 68 (58-77) Elevated β2-microglobulin, n (%) 27 (69) Male, n (%) 21 (54) High tumor burden by GELF criteria, n (%) 36 (92) White, n (%) 37 (95) POD2
Slide 58: ZYNLONTA + rituximab in r/r FL: Updated Efficacy Analysis
ZYNLONTA + rituximab in r/r FL: Updated Efficacy Analysis University of Miami phase 2 IIT in 2L+ FL 22nd International Workshop on Non-Hodgkin Lymphoma (iwNHL) highlights11 100 75 Events/N Month OS (95% CI) OS (%) 50 4/60 6 98.1 (87.1-99.7%) Median 12 93.6 (81.2-97.9%) follow-up 18 90.6 (76.6-96.4%)
Slide 59: ZYNLONTA + rituximab in r/r FL: Summary of Safety
ZYNLONTA + rituximab in r/r FL: Summary of Safety Most Common TEAEs Most Common TEAEs Most common Grade 1-2 and all Grade 3+ in 39 Evaluable Patients Most common Grade 1-2 and all Grade 3+ in 39 Evaluable Patients AEs, n (%) Grade 1-2 Grade 3 Grade 4 AEs, n (%) Grade 1-2 Grade 3 Grade 4 Hematologica
Slide 60: ZYNLONTA + rituximab in r/r FL: Summary of Safety (cont)
ZYNLONTA + rituximab in r/r FL: Summary of Safety (cont) Most Common TEAEs Most common Grade 1-2 and all Grade 3+ in 39 Evaluable Patients 16 serious TEAEs occurred in 10 patients, with 4 (10%) considered to be AEs, n (%) Grade 1-2 Grade 3 Grade 4 related to study treatment Infections – othera 5 (13
Slide 61: Thank You
THERAPEUTICS Thank You B ZL
Slide 62: Glossary
Glossary ABC Activated B-cell Like GELF Groupe d'Etude des Lymphomes Folliculaires PR partial response Crite ria ADC antibody drug conjugate PRO patient reported outcomes GGT gamma-glutamyl transferase AE adverse event Q2W every two weeks HGBCL high grade B-ce ll lym phoma AESI adverse event of spec
ADC Therapeutics — Investor Presentation (August 2026) on 6ix